APA (7th ed.) Citation

A, L., EA, I., MP, W., AA, P., W, H., AM, B., . . . TO, C. (2022). Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. The Journal of clinical endocrinology and metabolism, 107(3), 813. https://doi.org/10.1210/clinem/dgab729

Chicago Style (17th ed.) Citation

A, Linglart, et al. "Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia." The Journal of Clinical Endocrinology and Metabolism 107, no. 3 (2022): 813. https://doi.org/10.1210/clinem/dgab729.

MLA (9th ed.) Citation

A, Linglart, et al. "Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia." The Journal of Clinical Endocrinology and Metabolism, vol. 107, no. 3, 2022, p. 813, https://doi.org/10.1210/clinem/dgab729.